Tretinoin nanogel 0.025% versus conventional gel 0.025% in patients with acne vulgaris: A randomized, active controlled, multicentre, parallel group, phase iv clinical trial

Journal of Clinical and Diagnostic Research

Volumn 9, Issue 1, 2015, Pages WC04-WC09

  Chandrashekha, B S ^a   Anitha, M ^b   Ruparelia, Mukesh ^c   Vaidya, Pradyumna ^d   Aamir, Riyaz ^e   Shah, Sunil ^f   Thilak, S ^g   Aurangabadkar, Sanjeev ^h   Pal, Sandeep ⁱ   Saraswat, Abir ^j   Jayesh, J ^k  

^a Cutis Clinic   (India)

^b Devarsh Cosmetic Care and Sliming Centre ^*  (India)

^c Devarsh Cosmetic Care and Sliming Centre   (India)

^d Skin Clinic   (India)

^e Skin Care Clinic   (India)

^f Shriji Skin care Clinic   (India)

^g SV Clinic   (India)

^h Skin and Laser Clinic   (India)

ⁱ Orange City Hospital   (India)

^j Indushree Skin Clinic   (India)

^k ZYDUS RESEARCH CENTRE   (India)

more..

Author keywords

Acne vulgaris; Nanogel; Tretinoin

Indexed keywords

RETINOIC ACID;

ACNE VULGARIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NANOGEL; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; TREATMENT OUTCOME;

HEDYOTIS MANNII;

EID: 84924858644     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2015/10663.5469     Document Type: Article

References (28)

1. Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998;351:1871-76
2. Koo J. The psychosocial impact of acne: patients' perceptions. J Am Acad Dermatol. 1995;32:S26-30
3. Quan M, Strick RA. Management of acne vulgaris. Am Fam Physician. 1988;38:207-18
4. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, et al. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2009;60:S1-50
5. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol. 1998;39:S38-44.
6. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther. 1992;14:773-80.
7. Leyden JJ. Retinoids and acne. J Am Acad Dermatol. 1988;19:164-68.
8. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol. 2005;174:2467-70.
9. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, multicenter comparison of two 0.025% tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol. 1998;38:S24-30.
10. Verschoore M, Bouclier M, Czernielewski J, Hensby C. Topical retinoids. Their uses in dermatology. Dermatol Clin. 1993;11:107-15
11. Berger R, Rizer R, Barba A, Wilson D, Stewart D, Grossman R, et al. Tretinoin gel microspheres 0.04% versus 0.1% in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial. Clin Ther. 2007;29:1086-97
12. Lucky AW, Cullen SI, Jarratt MT, Quigley JW. Comparative efficacy and safety of two 0.025% tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol. 1998;38:S17-23
13. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345:163-71.
14. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59:792-800.
15. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:73-81
16. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139:48-56
17. Patel VB, Misra A, Marfatia YS. Topical liposomal gel of tretinoin for the treatment of acne: research and clinical implications. Pharm Dev Technol. 2000;5(4):455-64.
18. Cunliffe WJ, Caputo R, Dreno B, Förström L, Heenen M, Orfanos CE, et al. Clinical efficacy and safety comparison of adapalene gel and tretinoin gel in the treatment of acne vulgaris: Europe and U.S. multicenter trials. J Am Acad Dermatol. 1997;36:S126-34.
19. Pannu J, Ciotti S, Eisma R, MA L, Sutcliffe J. In vitro Susceptibility of Propionibacterium acnes and Skin Permeation of NB-00X Formulations. Proceedings of 69th Annual Meeting of Society for Investigative Dermatology; 2009 May 06 - 09; Montreal, Canada. Available from URL: http://www.nanobio. com/news/documents/148098_616_11x17.pdf [accessed on 30 January 2013]
20. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328:191-95.
21. Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion. J Nanobiotechnology. 2008;6:8
22. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S. Nanoemulsions as vehicles for transdermal delivery of aceclofenac. AAPS Pharm Sci Tech. 2007;8:E104
23. Leyden JJ, Ijzerman MM, Flack MR, Baker JR. Evaluation of the safety and efficacy of a novel anti-acne nanoemulsion (NB-003) in a randomized, open-label, parallel-group, single center study. Proceedings of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2010 Sep 12-15; Boston, U.S.A. Available at: http://www.nanobio.com/news/documents/ ICAAC_2010_L1_1751_Acne.pdf. Accessed January 30, 2013.
24. Hamouda T, Myc A, Donovan B, Shih AY, Reuter JD, Baker JR Jr. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol Res. 2001;156:1-7.
25. Brisaert M, Plaizier-Vercammen J. Investigation on the photostability of a tretinoin lotion and stabilization with additives. Int J Pharm. 2000;199:49–57.
26. Nighland M, Yusuf M, Wisniewski S, Huddleston K, Nyirady J. The effect of simulated solar UV irradiation on tretinoin in tretinoin gel microsphere 0.1% and tretinoin gel 0.025%. Cutis. 2006;77:313-16.
27. Tretinoin [Summary of Product Characteristics]. Buckinghamshire UK: Janssen- Cilag Ltd.;2012.
28. Yamaguchi Y, Nagasawa T, Nakamura N, Takenaga M, Mizoguchi M, Kawai S, et al. Successful treatment of photo-damaged skin of nano-scale at RA particles using a novel transdermal delivery. J Control Release. 2005;104:29-40.